evoxx technologies GmbH, a German industrial biotechnology company focusing on the development and production of enzymes and novel carbohydrate ingredients produced by its patented enzymatic bioconversion platform has announced the launch of its new website—www.evoxx.com. The website offers a complete company and product overview in German with English translation.
evoxx technologies, with two locations in Germany—on the creative campus in Monheim am Rhein, and on the biotech campus Hermannswerder in Potsdam, was formed following the acquisition of aevotis GmbH by evocatal GmbH. The new company’s vision is to become a leading provider of innovative enzyme and carbohydrate products for the nutritional health and wellness markets. A strong patent protected technology platform enables the development and marketing of exclusive carbohydrate oligomers and polymers for the global food market.
“In the functional food market we see an increasing demand for novel ingredients with strong scientifically supported health benefits,” said Dr. Thorsten Eggert, evoxx managing director and chief executive officer. “To meet the needs of its customers, the food industry needs novel and multi-functional ingredients which are in line with recent scientific findings and studies on healthy diets and we have the enzyme technology to do it.”
evoxx technologies GmbH will use its competitive enzyme and carbohydrate development expertise in applications to target the negative health effects of commonly over-consumed carbohydrates such as sucrose, glucose, fructose and/or from inadequate amount of dietary fiber.
“Within the next three years, evoxx will bring more healthy carbohydrates into the glass and onto the plate of the consumer by using enzymes and ingredients from the evoxx pipeline,” said Eggert.
As early as 2017, evoxx is scheduled to launch a slowly digestible oligosaccharide, as well as a highly active prebiotic oligosaccharide dietary supplement for gut health in the U.S.
The evoxx market focus will ensure continuity in cooperative projects with customers and partners. The proprietary technology platform of evocatal and aevotis will be applied by evoxx technologies to develop tailor-made enzymes and processes for various industries. evoxx technologies plans to enhance production capability to supply enzymes on an industrial scale for current and future customers.
“The combination of convenience and health is required,” noted Martina Doering, evoxx managing director and chief sales officer. “Consumers today expect food that delivers health benefits without changing taste and eating behavior and that’s what evoxx will provide.”
For more information, email firstname.lastname@example.org.